The downgrade from Outperform to Market Perform by a William Blair analyst could potentially lead to a decrease in the stock price of Travere Therapeutics in the short term. This is because such downgrades often reflect a less optimistic outlook for the company's performance, which can influence investor sentiment and trading behavior.